Argenx Se ( (ARGX) ) has provided an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks the first time the neonatal Fc receptor blocker has been authorized for CIDP treatment, providing patients with a convenient at-home self-injection option. The approval is based on the results of the ADHERE trial, which demonstrated significant clinical improvements in mobility, function, and reduction in relapse risk for patients treated with VYVDURA. This development strengthens Argenx’s position in the immunology market and expands treatment options for CIDP patients, while potentially impacting stakeholders by broadening access to innovative therapies.
More about Argenx Se
Argenx SE is a global immunology company dedicated to improving the lives of individuals suffering from severe autoimmune diseases. The company focuses on developing treatments that leverage its knowledge of immunology, with a particular emphasis on autoimmune disorders.
YTD Price Performance: 66.14%
Average Trading Volume: 265,255
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $38.01B
See more data about ARGX stock on TipRanks’ Stock Analysis page.
